Declared Dividend • Jun 15
Dividend of CN¥0.03 announced Dividend of CN¥0.03 is the same as last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (24% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.1% per year over the past 6 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 73% to shift the payout ratio to a potentially unsustainable range, which is more than the 13% EPS decline seen over the last 5 years. Valuation Update With 7 Day Price Move • May 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥6.81, the stock trades at a trailing P/E ratio of 27.2x. Average trailing P/E is 33x in the Healthcare industry in China. Total loss to shareholders of 3.1% over the past three years. Announcement • Apr 24
C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 14, 2026 C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 14, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Chongqing China Reported Earnings • Apr 24
First quarter 2026 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.10 (up from CN¥0.07 in 1Q 2025). Revenue: CN¥20.4b (flat on 1Q 2025). Net income: CN¥170.7m (up 36% from 1Q 2025). Profit margin: 0.8% (up from 0.6% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥6.49, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 31x in the Healthcare industry in China. Total returns to shareholders of 20% over the past three years. Announcement • Mar 31
C.Q. Pharmaceutical Holding Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 New Risk • Jan 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.4x net interest cover). Earnings have declined by 20% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change). Announcement • Jan 12
C.Q. Pharmaceutical Holding Co., Ltd. Announces Cash Dividend for Third Quarter of 2025 of A Shares, Payable on 16 January 2026 C.Q. Pharmaceutical Holding Co., Ltd. announced interim cash dividend/10 shares (tax included) of CNY0.30000000 for third quarter of 2025of A shares. Record date is 15 January 2026. Ex-date is 16 January 2026. Payment date is 16 January 2026. Announcement • Dec 31
C.Q. Pharmaceutical Holding Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026 Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥6.45, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 34x in the Healthcare industry in China. Total returns to shareholders of 17% over the past three years. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.06 (vs CN¥0.031 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.06 (up from CN¥0.031 in 3Q 2024). Revenue: CN¥21.0b (up 5.6% from 3Q 2024). Net income: CN¥101.7m (up 88% from 3Q 2024). Profit margin: 0.5% (up from 0.3% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • Sep 30
C.Q. Pharmaceutical Holding Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Reported Earnings • Aug 21
Second quarter 2025 earnings released: EPS: CN¥0.09 (vs CN¥0.08 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.09 (up from CN¥0.08 in 2Q 2024). Revenue: CN¥20.6b (up 2.1% from 2Q 2024). Net income: CN¥157.0m (up 16% from 2Q 2024). Profit margin: 0.8% (up from 0.7% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Jul 02
C.Q. Pharmaceutical Holding Co., Ltd. to Report First Half, 2025 Results on Aug 21, 2025 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report first half, 2025 results on Aug 21, 2025 Announcement • May 16
C.Q. Pharmaceutical Holding Co., Ltd. Approves Cash Dividend for 2024 C.Q. Pharmaceutical Holding Co., Ltd. at its Annual General Meeting held on 14 May 2025 approved cash dividend of CNY 0.30000000 per 10 shares (tax included) for 2024. Announcement • Apr 25
C.Q. Pharmaceutical Holding Co., Ltd. Proposes Final Cash Dividend for 2024 C.Q. Pharmaceutical Holding Co., Ltd. proposed final cash dividend of CNY 0.30000000 per 10 shares (tax included) for 2024. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.07 (vs CN¥0.06 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.07 (up from CN¥0.06 in 1Q 2024). Revenue: CN¥20.6b (up 5.0% from 1Q 2024). Net income: CN¥125.2m (up 22% from 1Q 2024). Profit margin: 0.6% (up from 0.5% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • Apr 24
C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 14, 2025 C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China New Risk • Apr 15
New major risk - Revenue and earnings growth Earnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Earnings have declined by 5.0% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (181% cash payout ratio). Profit margins are more than 30% lower than last year (0.5% net profit margin). Announcement • Mar 31
C.Q. Pharmaceutical Holding Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025 Announcement • Dec 31
C.Q. Pharmaceutical Holding Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025 Announcement • Oct 26
C.Q. Pharmaceutical Holding Co., Ltd. Proposes Third Quarter Dividend for the Third Quarter of 2024 C.Q. Pharmaceutical Holding Co., Ltd. proposed third quarter Cash dividend/10 shares (tax included): CNY0.30000000 for the third quarter of 2024. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.031 (vs CN¥0.002 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.031 (up from CN¥0.002 in 3Q 2023). Revenue: CN¥19.9b (up 13% from 3Q 2023). Net income: CN¥54.1m (up CN¥50.2m from 3Q 2023). Profit margin: 0.3% (up from 0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Sep 30
C.Q. Pharmaceutical Holding Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥5.76, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Healthcare industry in China. Total returns to shareholders of 20% over the past three years. New Risk • Sep 04
New major risk - Revenue and earnings growth Earnings have declined by 2.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). Earnings have declined by 2.3% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (0.5% net profit margin). Reported Earnings • Aug 21
Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.18 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.08 (down from CN¥0.18 in 2Q 2023). Revenue: CN¥20.2b (down 4.5% from 2Q 2023). Net income: CN¥135.1m (down 61% from 2Q 2023). Profit margin: 0.7% (down from 1.6% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Jun 29
C.Q. Pharmaceutical Holding Co., Ltd. to Report First Half, 2024 Results on Aug 21, 2024 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report first half, 2024 results on Aug 21, 2024 Announcement • Jun 01
C.Q. Pharmaceutical Holding Co., Ltd. Implements Final Cash Dividend of A Shares for 2023, Payable on 6 June 2024 C.Q. Pharmaceutical Holding Co., Ltd. implemented final cash dividend of A shares of CNY 0.5000000 per 10 shares (tax included) for 2023. Record date: 5 June 2024. Ex-date: 6 June 2024. Payment date: 6 June 2024. Announcement • Apr 29
C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 17, 2024 C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 17, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.10 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.06 (down from CN¥0.10 in 1Q 2023). Revenue: CN¥19.6b (flat on 1Q 2023). Net income: CN¥103.0m (down 38% from 1Q 2023). Profit margin: 0.5% (down from 0.8% in 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Mar 30
C.Q. Pharmaceutical Holding Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Announcement • Dec 30
C.Q. Pharmaceutical Holding Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 Announcement • Dec 02
C.Q. Pharmaceutical Holding Co., Ltd. Announces Executive Appointments C.Q. Pharmaceutical Holding Co., Ltd. at the Extraordinary General Meeting held on 30 November 2023 approved election of non-independent directors, cumulative voting system applicable: Chen Yihai; Election of independent directors, cumulative voting system applicable: Chen Fengwen, Liu Shengqiang, Liu Hong and Cai Zhongxi. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.16 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.002 (down from CN¥0.16 in 3Q 2022). Revenue: CN¥17.7b (flat on 3Q 2022). Net income: CN¥3.95m (down 99% from 3Q 2022). Profit margin: 0% (down from 1.6% in 3Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 2% per year. Reported Earnings • Aug 25
Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.18 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.18 in 2Q 2022). Revenue: CN¥21.1b (up 26% from 2Q 2022). Net income: CN¥347.6m (up 20% from 2Q 2022). Profit margin: 1.6% (down from 1.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥5.47, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 24x in the Healthcare industry in China. Total loss to shareholders of 1.0% over the past three years. New Risk • Jul 13
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.0% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.4% average weekly change). Announcement • Jul 06
C.Q. Pharmaceutical Holding Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 11 July 2023 C.Q. Pharmaceutical Holding Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 0.60000000 for the year 2022, payable on 11 July 2023. Record date is 10 July 2023. Ex-date is 11 July 2023. Board Change • Jun 28
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Yun Wei was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • May 20
C.Q. Pharmaceutical Holding Co., Ltd. Approves Cash Dividend for 2022 C.Q. Pharmaceutical Holding Co., Ltd. approved cash dividend of CNY 0.60000000 per 10 shares (tax included) for 2022 at AGM held on May 18, 2023. Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.06 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.10 (up from CN¥0.06 in 1Q 2022). Revenue: CN¥19.6b (up 24% from 1Q 2022). Net income: CN¥166.0m (up 48% from 1Q 2022). Profit margin: 0.8% (up from 0.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 15% per year. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥7.03, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 30x in the Healthcare industry in China. Total returns to shareholders of 44% over the past three years. Board Change • Oct 31
High number of new directors Non Independent Director Cong Zhang was the last director to join the board, commencing their role in 2021. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.14 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.14 in 3Q 2021). Revenue: CN¥17.9b (up 11% from 3Q 2021). Net income: CN¥378.8m (up 55% from 3Q 2021). Profit margin: 2.1% (up from 1.5% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.18 (down from CN¥0.19 in 2Q 2021). Revenue: CN¥16.8b (up 7.4% from 2Q 2021). Net income: CN¥289.1m (down 19% from 2Q 2021). Profit margin: 1.7% (down from 2.3% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • Aug 26
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non Independent Director Cong Zhang was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥5.89, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 31x in the Healthcare industry in China. Total returns to shareholders of 8.5% over the past three years. Announcement • Jun 21
C.Q. Pharmaceutical Holding Co., Ltd. Announces Implementation of 2021 Final Profit Distribution Plan, Payable on 28 June 2022 C.Q. Pharmaceutical Holding Co., Ltd. announced 2021 final profit distribution plan to be implemented (A shares) as cash dividend (tax included) of CNY 0.65000000 per ten shares. The record date is 27 June 2022, ex-date is 28 June 2022, and payment date is 28 June 2022. Announcement • May 24
C.Q. Pharmaceutical Holding Co., Ltd. Announces Cash Dividend for 2021 C.Q. Pharmaceutical Holding Co., Ltd. announced Cash dividend/10 shares (tax included) of CNY 0.65000000 for 2021. Announcement • May 08
C.Q. Pharmaceutical Holding Co., Ltd. Proposes Dividend for 2021 C.Q. Pharmaceutical Holding Co., Ltd. proposed Cash dividend/10 shares (tax included) of CNY 0.65000000 for 2021. Announcement • May 07
C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 20, 2022 C.Q. Pharmaceutical Holding Co., Ltd., Annual General Meeting, May 20, 2022, at 14:30 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 work report of the supervisory committee ; to consider 2021 internal control evaluation report;to consider Continuing connected transactions with a company; to consider 2021 annual accounts; to consider 2022 budget report; to consider 2021 annual report and its summary;to consider 2021 profit distribution plan and to consider Implementing results of 2021 continuing connected transactions and estimation of 2022 continuing connected transactions. Reported Earnings • May 02
First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.05 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.06 (up from CN¥0.05 in 1Q 2021). Revenue: CN¥15.9b (up 9.7% from 1Q 2021). Net income: CN¥111.9m (up 41% from 1Q 2021). Profit margin: 0.7% (up from 0.5% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 28% share price gain to CN¥6.38, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 27x in the Healthcare industry in China. Total returns to shareholders of 4.3% over the past three years. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥6.15, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 29x in the Healthcare industry in China. Total returns to shareholders of 7.0% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.18 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥16.1b (up 21% from 3Q 2020). Net income: CN¥243.8m (down 22% from 3Q 2020). Profit margin: 1.5% (down from 2.3% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.12 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥15.6b (up 66% from 2Q 2020). Net income: CN¥358.3m (up 66% from 2Q 2020). Profit margin: 2.3% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.05 in 1Q 2020) The company reported a mediocre first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CN¥14.5b (up 89% from 1Q 2020). Net income: CN¥79.5m (down 5.5% from 1Q 2020). Profit margin: 0.5% (down from 1.1% in 1Q 2020). The decrease in margin was driven by higher expenses. Announcement • Feb 25
C.Q. Pharmaceutical Holding Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report fiscal year 2020 results on Mar 30, 2021 Is New 90 Day High Low • Jan 11
New 90-day low: CN¥4.98 The company is down 13% from its price of CN¥5.74 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 12% over the same period. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥5.12 The company is down 9.0% from its price of CN¥5.61 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 15% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥754.7m, down 15% from the prior year. Total revenue was CN¥39.1b over the last 12 months, up 20% from the prior year. Announcement • Aug 02
C.Q. Pharmaceutical Holding Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020 C.Q. Pharmaceutical Holding Co., Ltd. announced that they will report first half, 2020 results on Aug 25, 2020